144 related articles for article (PubMed ID: 20354176)
1. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone.
Rigel DF; Fu F; Beil M; Hu CW; Liang G; Jeng AY
J Pharmacol Exp Ther; 2010 Jul; 334(1):232-43. PubMed ID: 20354176
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
Fiebeler A; Nussberger J; Shagdarsuren E; Rong S; Hilfenhaus G; Al-Saadi N; Dechend R; Wellner M; Meiners S; Maser-Gluth C; Jeng AY; Webb RL; Luft FC; Muller DN
Circulation; 2005 Jun; 111(23):3087-94. PubMed ID: 15939810
[TBL] [Abstract][Full Text] [Related]
3. Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates.
Weldon SM; Cerny MA; Gueneva-Boucheva K; Cogan D; Guo X; Moss N; Parmentier JH; Richman JR; Reinhart GA; Brown NF
J Pharmacol Exp Ther; 2016 Oct; 359(1):142-50. PubMed ID: 27481775
[TBL] [Abstract][Full Text] [Related]
4. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.
Adams CM; Hu CW; Jeng AY; Karki R; Ksander G; Lasala D; Leung-Chu J; Liang G; Liu Q; Meredith E; Rao C; Rigel DF; Shi J; Smith S; Springer C; Zhang C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4324-7. PubMed ID: 20615692
[TBL] [Abstract][Full Text] [Related]
5. Increased adrenal androgen secretion with inhibition of 11beta-hydroxylase in HIV-infected women.
Koutkia P; Berry J; Eaton K; Breu J; Grinspoon S
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E808-13. PubMed ID: 16303845
[TBL] [Abstract][Full Text] [Related]
6. Hyperreninemic hypoaldosteronism after chronic stress in the rat.
Aguilera G; Kiss A; Sunar-Akbasak B
J Clin Invest; 1995 Sep; 96(3):1512-9. PubMed ID: 7657823
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.
LaSala D; Shibanaka Y; Jeng AY
Anal Biochem; 2009 Nov; 394(1):56-61. PubMed ID: 19622340
[TBL] [Abstract][Full Text] [Related]
8. In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase.
Lehner MD; Marx D; Boer R; Strub A; Hesslinger C; Eltze M; Ulrich WR; Schwoebel F; Schermuly RT; Barsig J
J Pharmacol Exp Ther; 2006 Apr; 317(1):181-7. PubMed ID: 16368897
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
[TBL] [Abstract][Full Text] [Related]
10. The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice.
Hofmann A; Brunssen C; Peitzsch M; Balyura M; Mittag J; Frenzel A; Jannasch A; Brown NF; Weldon SM; Gueneva-Boucheva KK; Eisenhofer G; Bornstein SR; Morawietz H
Horm Metab Res; 2017 Jun; 49(6):466-471. PubMed ID: 28427090
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.
Schumacher CD; Steele RE; Brunner HR
J Hypertens; 2013 Oct; 31(10):2085-93. PubMed ID: 24107737
[TBL] [Abstract][Full Text] [Related]
12. Partial protection from organophosphate-induced cholinesterase inhibition by metyrapone treatment.
Swiercz R; Lutz P; Gralewicz S; Grzelińska Z; Piasecka-Zelga J; Wąsowicz W
Int J Occup Med Environ Health; 2013 Aug; 26(4):636-46. PubMed ID: 24052154
[TBL] [Abstract][Full Text] [Related]
13. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
15. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
16. Mutations in aldosterone synthase gene of Milan hypertensive rats: phenotypic consequences.
Lloyd-MacGilp SA; Torielli L; Bechtel S; Tripodi G; Gomez-Sanchez CE; Zagato L; Bernhardt R; Kenyon CJ
Am J Physiol Endocrinol Metab; 2002 Mar; 282(3):E608-17. PubMed ID: 11832364
[TBL] [Abstract][Full Text] [Related]
17. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
18. Investigation of aldosterone-synthase inhibition in rats.
Ménard J; Gonzalez MF; Guyene TT; Bissery A
J Hypertens; 2006 Jun; 24(6):1147-55. PubMed ID: 16685215
[TBL] [Abstract][Full Text] [Related]
19. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice.
Gamliel-Lazarovich A; Gantman A; Coleman R; Jeng AY; Kaplan M; Keidar S
J Hypertens; 2010 Sep; 28(9):1900-7. PubMed ID: 20699715
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone synthase inhibition in humans.
Azizi M; Amar L; Menard J
Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
